Optimising Patient Selection for Polyacrylamide Hydrogel Injections to Delay Total Knee Replacement in UK Knee Osteoarthritis Patients
Polyacrylamide hydrogel (PAAG) injections offer a promising, minimally invasive alternative for managing knee osteoarthritis (OA), with the potential to delay or reduce the need for total knee replacement (TKR) surgery. Recent studies highlight that carefully selected patients—older individuals, those with bilateral and milder OA, and non-diabetics—may experience effective, longer-lasting symptom relief and improved quality of life. PAAG acts as a supportive shock absorber within the joint, setting it apart from traditional therapies. By postponing surgery, PAAG can provide significant cost savings and reduce strain on NHS resources. While current evidence supports its efficacy and safety, further controlled trials are needed to determine long-term outcomes and optimal patient selection. PAAG injections could become an important tool in modern knee OA treatment strategies.
